Publication Name	World Journal of Gastroenterology
Manuscript ID	61095
Country	United Kingdom

Category	Oncology
Manuscript Type	Observational Study
Article Title	Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment
Manuscript Source	Invited Manuscript
All Author List	Angela Lamarca, Mauro Cives, Louis de Mestier, Joakim Crona, Francesca Spada, Kjell Öberg, Marianne Pavel and Teresa Alonso-Gordoa
Funding Agency and Grant Number
Corresponding Author	Angela Lamarca, MD, MSc, PhD, Senior Lecturer, Department of Medical Oncology, European Neuroendocrine Tumor Society Centre of Excellence, The Christie NHS Foundation Trust, University of Manchester, Manchester M20 4BX, United Kingdom. angela.lamarca@nhs.net
Key Words	Neuroendocrine tumour; Small bowel; Survey; Third-line; Advanced; Practice
Core Tip	Our survey delineates a possible treatment algorithm in patients with advanced small bowel neuroendocrine tumour (SBNET). While somatostatin analogues (SSAs), peptide receptor radionuclide therapy (PRRT) and everolimus are usually considered preferred first, second and third-line options respectively, chemotherapy is generally used when all other available treatments have failed. Locoregional therapies appear particularly useful when facing patients with functioning tumours, but their use is mainly limited to after at least two prior lines of treatment. We were also able to identify relevant unanswered questions in the field of advanced SBNET treatment, mainly in regards to the role of maintenance SSA after PRRT for non-functioning tumours. Multiple factors were identified as relevant at time of decision making; among them, Ki-67, rate of progression, tumour functionality and tumour burden may have a key role in helping physicians tailoring the treatment. Based on this, we would encourage for treatment decisions to be made within a multidisciplinary setting.
Citation	Lamarca A, Cives M, de Mestier L, Crona J, Spada F, Öberg K, Pavel M, Alonso-Gordoa T. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd line treatment. World J Gastroenterol 2021; 27(10): 976-989

Received	2020-11-23 15:03
Peer-Review Started	2020-11-23 15:04
To Make the First Decision
Return for Revision	2021-01-07 01:33
Revised	2021-01-12 08:23
Second Decision	2021-02-25 12:58
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-02-26 19:48
Articles in Press	2021-02-26 19:48
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-03-09 04:30

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com